BiotechTube
Richter Gedeon

Richter Gedeon

RIG2.FPhase 3
10,000-15,000 employeesrichter.hu

Richter Gedeon Plc is Hungary's largest pharmaceutical company with over 120 years of experience in drug development and manufacturing. The company has built a strong international presence through strategic partnerships and acquisitions, with operations spanning Europe, Asia, and the Americas. Richter is particularly known for its expertise in women's healthcare products, including contraceptives and hormone replacement therapies, as well as treatments for neurological and cardiovascular conditions.

Market Cap
$6.3B
+11.6% period
Pipeline
34
11 in Phase 3
Patents
1
granted
Publications
20
indexed

RIG2.F · Stock Price

USD 29.48+3.06 (+11.58%)

Historical price data

AI Company Overview

Richter Gedeon Plc is Hungary's largest pharmaceutical company with over 120 years of experience in drug development and manufacturing. The company has built a strong international presence through strategic partnerships and acquisitions, with operations spanning Europe, Asia, and the Americas. Richter is particularly known for its expertise in women's healthcare products, including contraceptives and hormone replacement therapies, as well as treatments for neurological and cardiovascular conditions.

Women's HealthcareCentral Nervous SystemCardiovascularGeneric Pharmaceuticals

Technology Platform

Integrated pharmaceutical development and manufacturing with expertise in synthetic chemistry, formulation development, and proprietary drug delivery systems for complex therapeutic molecules.

Pipeline

34
34 drugs in pipeline11 in Phase 3
DrugIndicationStageWatch
spironolactoneHypertensionApproved
Myo-inositol + Clomiphene CitrateOvulation InductionApproved
CariprazineBipolar I DisorderPhase 3
Placebo + CariprazineSchizophreniaPhase 3
RGB-14-P + Prolia®Postmenopausal OsteoporosisPhase 3

Funding History

1
IPOUndisclosedJun 15, 1997

Opportunities

Richter has significant growth opportunities through international expansion of Cariprazine, development of new women's healthcare products, and strategic partnerships for innovative drug development.
The company's strong position in emerging markets provides access to rapidly growing healthcare systems.

Risk Factors

Key risks include increasing generic competition pressuring margins, regulatory changes across multiple international markets, and clinical development risks associated with pipeline programs.
Currency fluctuations from international operations also present ongoing financial risk.

Competitive Landscape

Richter competes with multinational pharmaceutical companies like Teva and Sandoz, as well as regional players like KRKA in Central and Eastern Europe. The company differentiates through its proprietary products like Cariprazine, cost-effective manufacturing, and strong regional market positions in women's healthcare and CNS disorders.